Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeKCIKCI Enters Into a Performance-Based Agreement with Highmark for the KCI iOn PROGRESS Remote Therapy Monitoring Program

KCI Enters Into a Performance-Based Agreement with Highmark for the KCI iOn PROGRESS Remote Therapy Monitoring Program

December 18, 2018

KCI, an Acelity Company, a global leader in advanced wound management, and Highmark Inc., a national diversified health care insurance provider, have entered into a performance-based agreement for the KCI iOn PROGRESS™ Remote Therapy Monitoring Program.

The program aims to improve overall patient experience, while lowering costs through increased engagement and adherence.  Used in conjunction with the ACTIV.A.C.™ Therapy System, iOn PROGRESS™ Remote Therapy Monitoring Program consists of 3 key components:

  • Monitoring: A proprietary remote monitoring module attached to the ACTIV.A.C.™ Therapy device enables secure transmission of therapy data to KCI.
  • Engagement: A highly trained team of KCI Virtual Therapy Specialists (VTS) analyze the data and interact directly with patients and healthcare professionals to support adherence.
  • Adherence: 73% of patients demonstrated an increase in hours of NPWT use per day following an adherence call from a Virtual Therapy Specialist. A lower average 90-day wound-related cost was associated with those receiving remote therapy monitoring.1

The agreement is the first-of-its-kind for negative pressure wound therapy (NPWT) and creates a performance-based payment structure for reducing total wound care costs. The partnership is a result of a diligent evaluation process by Highmark to understand how the iOn PROGRESS™ Remote Therapy Monitoring Program impacts its members in alignment with their commitment to improve quality while lowering total cost of care.

“The collaboration and agreement with KCI is just the latest example of Highmark’s commitment to working with providers in the health care industry to make sure our members receive high-quality care at an affordable price,” said Robert Wanovich, VP of Ancillary Provider Strategy & Management, Highmark Inc.

“Since introducing the iOn PROGRESS™ Remote Therapy Monitoring System two years ago, we have learned a great deal about our NPWT patients through their engagements with our Virtual Therapy Specialist team – all of which have helped us develop and improve an impactful solution,” said R. Andrew Eckert, President and CEO, KCI. “Our aim is to create value across the continuum of wound care and iOn PROGRESS™ Remote Therapy Monitoring allows us to pursue that by better understanding each patient’s wound care journey. This unique insight allows us to engage patients and their caregivers like no other and better assist them through the healing process, which leads to better therapy adherence and ultimately, better outcomes and reduced costs.”

In October, KCI reached a milestone of 10,000 patients monitored using iOn PROGRESS™ Remote Therapy Monitoring and in November, showcased the program at SAWC Fall, providing clinicians an inside look at the patients’ experience using NPWT through a poster presentation and interactive booth experience.

The ACTIV.A.C.™ Therapy System with iOn PROGRESS™ Remote Therapy Monitoring is the first system to remotely monitor therapy usage for patients prescribed NPWT in the home. It monitors therapy adherence and securely transmits data to the KCI iOn PROGRESS™ Care Network, a group of highly-trained individuals who interact with patients to drive adherence. Recent studies show 79% of NPWT patients require an adherence call from a KCI VTS during their NPWT episode and the average increase in NPWT the day following an adherence call is 104%.2 


References

1 Griffin L. Evaluation of Cost of Care Between Patients With and Without Remote Therapy Monitoring. HEOR-2018-002-DAR. 09Aug2018.

2 Griffin L. Leyva-Casillas L. A Patient-centered Remote Therapy Monitoring Program Focusing on Increased Adherence to Wound Therapy: A Large Cohort Study. Wounds. 2018;30(8):E81-E83.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy